Literature DB >> 23523856

Downregulation of Axl in non-MYCN amplified neuroblastoma cell lines reduces migration.

Floor A M Duijkers1, Jules P P Meijerink, Rob Pieters, Max M van Noesel.   

Abstract

Neuroblastomas (NBL) are common pediatric solid tumors with a variable clinical course. At diagnosis half of all neuroblastoma patients presents with metastatic disease. The mechanisms of metastasis are largely unknown. Gene expression profiles (HU133plus2.0 arrays, Affymetrix) of 17 NBL and 5 peripheral neuro-ectodermal cell lines were used to identify a subgroup of non-MYCN amplified (non-NMA) NBL cell lines with a distinct gene expression profile and characterized by high expression of AXL. Axl is a tyrosine kinase receptor which plays a role in the metastatic process of several types of cancer. We hypothesized that Axl contributes to the metastasizing potential of non-NMA NBL and tested if AXL silencing diminishes malignant properties of high Axl expressing cell lines. AXL was silenced in two non-NMA NBL cell lines by using a lentiviral shRNA construct that was able to transduce these cell lines with more than 90% infection efficiency. Axl mRNA and protein level were efficiently knocked-down resulting in a decrease of migration of Axl positive cell lines GI-M-EN and SH-EP-2, and decreased invasion of GI-M-EN. Morphologically, Axl knockdown induced more rounded cells with a loss of contact. Intracellularly, we observed induction of stress fibers (immunofluorescence F-actin). These changes in cytoskeleton were associated with decreased migration, but were not accompanied by changes in genes involved in epithelial to mesenchymal transition such as CDH2, VIM or MMP9. No effects were observed for cell proliferation, apoptosis or downstream pathways. In conclusion, AXL is identified as a possible mediator of NBL metastasis.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23523856     DOI: 10.1016/j.gene.2013.03.029

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  5 in total

Review 1.  TYRO3: A potential therapeutic target in cancer.

Authors:  Pei-Ling Hsu; Jonathan Jou; Shaw-Jenq Tsai
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-02

2.  Targeting TYRO3 inhibits epithelial-mesenchymal transition and increases drug sensitivity in colon cancer.

Authors:  C-W Chien; P-C Hou; H-C Wu; Y-L Chang; S-C Lin; S-C Lin; B-W Lin; J-C Lee; Y-J Chang; H S Sun; S-J Tsai
Journal:  Oncogene       Date:  2016-05-02       Impact factor: 9.867

3.  ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT.

Authors:  D N Debruyne; N Bhatnagar; B Sharma; W Luther; N F Moore; N-K Cheung; N S Gray; R E George
Journal:  Oncogene       Date:  2015-11-30       Impact factor: 9.867

4.  Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors.

Authors:  Sanja Aveic; Marcella Pantile; Pierfrancesco Polo; Viktoryia Sidarovich; Marilena De Mariano; Alessandro Quattrone; Luca Longo; Gian Paolo Tonini
Journal:  Cancer Cell Int       Date:  2018-04-24       Impact factor: 5.722

Review 5.  ALK in Neuroblastoma: Biological and Therapeutic Implications.

Authors:  Ricky M Trigg; Suzanne D Turner
Journal:  Cancers (Basel)       Date:  2018-04-10       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.